Member Info for VP007

Do we still see the StoneChecker business as core to IB?

I understand that we decided to keep the company and upgrade the product, but I can’t help think whether this was grow a customer base and make it more attractive to a potential buyer (if offered again).

The alternative is that they continue to grow multiple arms of their portfolio with neurology, kidney and liver based products.

Quiet day today....

What are peoples thoughts on rumours of BRH/RMS taking a stake within the firm?

Any other thoughts on what caused the flurry of buying at the end of last year and early this year?

I would like to see us back in the 20s by January and then for us to steadily increase from there as we near the end of year financials in May.

LargeGin,

Agreed.

Give it time and people will start waking up to the opportunity here.

The fact that the product can run on existing medical equipment or via cloud (which basically means scan anywhere and analyse in the cloud) really opens up the possibilities here.

IB have been really smart here to get the infrastructure and pipeline established over 2020 e.g. cloud distribution, development and regulatory approval experience.

For me this is akin to how Amazon established its distribution infrastructure and is now reaping the rewards of various products and marketplaces leveraging this infrastructure.

IB has an opportunity to build (or acquire) additional AI algorithms in other medical fields and accelerate their route to market over competitors.

One hopes that the board are positioning to take advantage of this unique opportunity over 2021.

Jimzi,

Fully agreed. I wouldn’t be worried by the conversions due to TB retaining his holding.

I would be more worried if TB, Michael, his wife etc. started selling their holdings (and they didn’t even when we hit the 20s).

They can all see the potential value and growth of the company and are staying put. We should too as this could turn out to be a once in a lifetime opportunity.

If you look over the transaction histories there were a lot of small buys e.g 10s and 20s that walked the price down. This coupled with the heavy selling is a result of where we are with the share price at the moment.

In the short term we will see a rise, but whether it will be a spike or sustained is anyone’s guess.

The big unknown is what TB will do with the company. His recent actions have not been so popular with PIs in his other companies.

On the horizon I can see:

- confirmation of sales for both IB Clinic 2.0 software suite, StoneChecker 2.0 and new sales for the LSN software.
- further development of telehealth solutions
- completion of the gad free testing and FDA application of the solution
- development of IB Trax in partnership with the Mayo Clinic
- further awards of grants to cover R&D costs

The following statement is interesting within the Half Yesr report:

“Finally, we remain alert to the myriad of new companies creating innovative solutions that solve healthcare problems and aid patients. While we are excited about our organic growth potential, we recognize that merger and acquisition activity may accelerate revenue generation, fulfill technical gaps, and a potentially faster time to market. Expanding our footprint in medical imaging to better serve patients remains our unwavering goal, and we will remain aggressive in this pursuit.”

IB currently have a global distribution agreement with AI Metrics LLC for the LSN software, but wondering whether IB could go the full distance and enter into a merger or acquisition.

AI Metrics recently obtained $1.7M seed funding to further develop their AI based solutions.

This company could continue to help IB enter into new areas of healthcare and the application of AI.

Anyone got any other thoughts on what the above paragraph could be hinting towards?

Do we not think this will get back to 13p at least?

It wouldn’t have been a great deal for the Mayo Clinic to get the shares at the price.

Really could do with that bounce junior007!

Such great tech and more certainty in UK markets following the brexit deal, this should be going north now.

This illustrates the power of AI, to identify the patterns which humans and/or conventional methods are unable to identify easily.

The key to AI decision making accuracy is the data for which it is trained on. This is where IB have a competitive advantage, with access to some of the greatest minds, clinics and datasets in this field.

2021 needs to be the year IQAI capitalises on their technology and starts to get noticed for their offering both from end customers and potential acquirers for the firm.

Fingers crossed.

There is a lot of uncertainty in the markets today, so finishing blue is always nice to see.

Thanks Mickey.

It will be interesting to see how it plays out.

As it is with all of TBs companies, it can be a risk investing as you don’t know what is round the corner, however there is still money to be made on the way.

As I understand, TB sold his holdings within RMS.

Does he still have a vested interest in the success of the company or is he now focusing on BRH, IQAI or something else?

It’s good to see some buys going through today.

Volume is extremely low though and it will remain quiet until news.

Good point iknownuffin.

Out of interest, what is driving your timeline of middle of next year for a takeover.

I would have expected 2020 end of year results will be published in May 2021 and for those not to include a huge amount of sales from this year. August next year will be 2021 half year report and would hopefully show a trajectory of revenue which is higher than 2020.

Just wondering if by the 2021 half year report, whether there will be a strong enough revenue stream and future pipeline for a buyer to want to takeover the company at this point.

The counter argument to the above is that a buyer takes over the company based on the future revenue potential earlier within 2021.

I do believe something like this will play out as TB, Michael and his wife are all holding onto their stakes currently.

Yes would have been great if TB could find a way to give us IQAI holders a special dividend too :-)))

What are folks predictions for news on sales, partnerships etc.?

Before end of 2020 or early 2021?

I’m going with early 2021 and would love to be proven wrong!

Many thanks for confirming.

We really need some nuggets of good news to bring the buying pressure back here.

Interesting I noticed that IB published its EULA for IB Clinic 2.0 software on the 20th November before the official RNS on the 26th November. This could have been the reason for the share increase around that time.

It shows that some of these nuggets are out there and we need to do some more in depth research.

Can someone confirm if circa 900K shares were bought around 8:22 today (in a number of 10.40p and 10.30p chunks)?

ADVFN lists them on its trades.

If they were buys, someone is confident and this is in contrast to the current declining share price.